AstraZeneca shares rise after Phase 3 Tagrisso win
AstraZeneca (NYSE:AZN) priced its stock at $161.62 after reporting another Phase 3 victory Tuesday, saying Tagrisso plus Orpathys from Hutchmed delayed disease progression versus Tagrisso alone in previously untreated patients.
AstraZeneca NYSE:AZN, the global oncology and biopharmaceutical powerhouse, delivered another Phase 3 victory Tuesday, with its stock priced at $161.62.
Tagrisso combined with Hutchmed's Orpathys significantly delayed disease progression compared with Tagrisso alone in previously untreated patients…